Thomas Reiberger

IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.

Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.

Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.

Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.

von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.

Prognostic value of indeterminate IFN-γ release assay results in HIV-1 infection.

A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.

Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.

Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.

Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.

Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.

Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.

Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.

IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians.

Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.

Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3.

New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension.

Reply: To PMID 24631577.

Acute hepatitis C virus infection in HIV-infected men who have sex with men: should we change our screening practice?

Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.

PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension.

Chronic hepatitis C: treat everyone now or stratify by disease?

Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.

Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites.

Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.

Butyrylcholinesterase predicts cardiac mortality in young patients with acute coronary syndrome.

Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.

Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine.

Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.

An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.

Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals.

The profile of platelet α-granule released molecules affects postoperative liver regeneration.

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.

Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.

Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.

Advances in the management of HIV/HCV coinfection.

Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.

Assessment of response to beta-blockers by expression of βArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.

Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.

Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.

The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.

von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy.

Nonselective beta blockers in patients with ascites: implications of a nationwide study.

Metabolic preconditioning protects BSEP/ABCB11 mice against cholestatic liver injury.

Liver Capsule: FXR agonists against liver disease.

Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.

Beta blockers and cirrhosis, 2016.

Beta adrenergic blockade and decompensated cirrhosis.

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.

The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.

New liver - Fresh microbiome: Implications on brain function.

Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.

Reply to: "Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?"

Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.

Acid-base disorders in liver disease.

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.

Management of portal hypertension before and after liver transplantation.

Reply to: "Non selective beta blockers in cirrhosis".

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.

Role of diuretics in the harmful effects of beta blockers in patients with ascites. Author's reply.

Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection.

Transferrin as a predictor of survival in cirrhosis.

Peptic ulcer bleeding in patients with cirrhosis: Is it as bad as variceal bleeding?

The role of TIPS in the management of liver transplant candidates.

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.

Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.

When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome?

Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment-A multicenter retrospective study.

Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome.

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.

Animal models of portal hypertension.

Liver disease in adults with α1-antitrypsin deficiency.

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.

Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI.

Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.

Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Authors' reply.

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis.

Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study.

Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure.

De-Ritis Ratio Improves Long-Term Risk Prediction after Acute Myocardial Infarction.

Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?

Elastography-based screening for esophageal varices in patients with advanced chronic liver disease.

Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.

High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.

Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.

C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.

Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.

Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites.

Vascular Targets for the Treatment of Portal Hypertension.

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.

Guideline-conform statin use reduces overall mortality in patients with compensated liver disease.

The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease.

Detection of Various Microplastics in Human Stool: A Prospective Case Series.

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease.

HCV-RNA is commonly detectable in rectal and nasal fluids of patients with high viremia.

Editorial: pressure to close the therapeutic window of non-selective beta blockers?

Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient.

Gut-liver axis signaling in portal hypertension.

The impact of hepatic steatosis on portal hypertension.

Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?

The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.

Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction.

The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.

Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease.

Portal hypertensive gastropathy is associated with iron deficiency anemia.

Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population.

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.

Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview.

Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.

Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.